Characteristics of 9 All of Us Participants With Severe Acute Respiratory Syndrome Coronavirus 2–Seropositive Blood Specimens Collected From 2 January to 18 March 2020
. | . | . | . | SARS-CoV-2 Assay . | |
---|---|---|---|---|---|
Participant . | Race/Ethnicity . | Age Group, y . | Sex at Birth . | Abbott Cut-off, 1.4) . | EUROIMMUN (Cut-off, 1.1) . |
1 | Black/African American | 45–49 | Female | 3.09 | 2.681 |
2 | Black/African American | 50–54 | Male | 3.99 | 1.416 |
3 | Black/African American | 55–59 | Male | 3.17 | 1.846 |
4 | Black/African American | 55–59 | Female | 1.83 | 2.487 |
5 | Black/African American | 60–64 | Female | 4.13 | 1.984 |
6 | Hispanic, Latino, or Spanish | 60–64 | Female | 4.01 | 1.544 |
7 | Hispanic, Latino, or Spanish | 70–74 | Male | 2.43 | 1.125 |
8 | White | 50–54 | Female | 3.76 | 1.449 |
9 | White | 65–69 | Male | 8.09 | 2.891 |
. | . | . | . | SARS-CoV-2 Assay . | |
---|---|---|---|---|---|
Participant . | Race/Ethnicity . | Age Group, y . | Sex at Birth . | Abbott Cut-off, 1.4) . | EUROIMMUN (Cut-off, 1.1) . |
1 | Black/African American | 45–49 | Female | 3.09 | 2.681 |
2 | Black/African American | 50–54 | Male | 3.99 | 1.416 |
3 | Black/African American | 55–59 | Male | 3.17 | 1.846 |
4 | Black/African American | 55–59 | Female | 1.83 | 2.487 |
5 | Black/African American | 60–64 | Female | 4.13 | 1.984 |
6 | Hispanic, Latino, or Spanish | 60–64 | Female | 4.01 | 1.544 |
7 | Hispanic, Latino, or Spanish | 70–74 | Male | 2.43 | 1.125 |
8 | White | 50–54 | Female | 3.76 | 1.449 |
9 | White | 65–69 | Male | 8.09 | 2.891 |
Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Characteristics of 9 All of Us Participants With Severe Acute Respiratory Syndrome Coronavirus 2–Seropositive Blood Specimens Collected From 2 January to 18 March 2020
. | . | . | . | SARS-CoV-2 Assay . | |
---|---|---|---|---|---|
Participant . | Race/Ethnicity . | Age Group, y . | Sex at Birth . | Abbott Cut-off, 1.4) . | EUROIMMUN (Cut-off, 1.1) . |
1 | Black/African American | 45–49 | Female | 3.09 | 2.681 |
2 | Black/African American | 50–54 | Male | 3.99 | 1.416 |
3 | Black/African American | 55–59 | Male | 3.17 | 1.846 |
4 | Black/African American | 55–59 | Female | 1.83 | 2.487 |
5 | Black/African American | 60–64 | Female | 4.13 | 1.984 |
6 | Hispanic, Latino, or Spanish | 60–64 | Female | 4.01 | 1.544 |
7 | Hispanic, Latino, or Spanish | 70–74 | Male | 2.43 | 1.125 |
8 | White | 50–54 | Female | 3.76 | 1.449 |
9 | White | 65–69 | Male | 8.09 | 2.891 |
. | . | . | . | SARS-CoV-2 Assay . | |
---|---|---|---|---|---|
Participant . | Race/Ethnicity . | Age Group, y . | Sex at Birth . | Abbott Cut-off, 1.4) . | EUROIMMUN (Cut-off, 1.1) . |
1 | Black/African American | 45–49 | Female | 3.09 | 2.681 |
2 | Black/African American | 50–54 | Male | 3.99 | 1.416 |
3 | Black/African American | 55–59 | Male | 3.17 | 1.846 |
4 | Black/African American | 55–59 | Female | 1.83 | 2.487 |
5 | Black/African American | 60–64 | Female | 4.13 | 1.984 |
6 | Hispanic, Latino, or Spanish | 60–64 | Female | 4.01 | 1.544 |
7 | Hispanic, Latino, or Spanish | 70–74 | Male | 2.43 | 1.125 |
8 | White | 50–54 | Female | 3.76 | 1.449 |
9 | White | 65–69 | Male | 8.09 | 2.891 |
Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.